{"pmid":32438454,"title":"Management of osteoarthritis during COVID-19 pandemic.","text":["Management of osteoarthritis during COVID-19 pandemic.","The pandemic spread of the new COVID-19 coronavirus infection in China first, and all over the world at present, has become a global health emergency due to the rapidly increasing number of affected patients. Currently, a clear relationship between COVID-19 infection incidence and/or complications due to chronic or occasional treatments for other pathologies is still not clear, albeit COVID-19 pandemic may condition the treatment strategy of complex disorders, as osteoarthritis (OA). Importantly, OA is the most common age-related joint disease affecting more than 80% of people older than the age of 55, an age burden also shared with the highest severity in COVID-19 patients. OA patients often show a large array of concomitant pathologies such as diabetes, inflammation and cardiovascular diseases that are again shared with COVID-19 patients and may therefore increase complications. Moreover, different OA treatments such as NSAIDs, paracetamol, corticosteroids, opioids or other molecules have a wide array of iatrogenic effects, potentially increasing COVID-19 secondary infection incidence or complications. In this review we critically analyse the evidences on either negative or positive effect of drugs commonly used to manage OA in this particular scenario. This would provide orthopaedic surgeons at first, and physicians, pharmacologists and clinicians at general, a comprehensive description about the safety of the current pharmacological approaches and a decision making tool to treat their OA patients as the coronavirus pandemic continues.","Clin Pharmacol Ther","Ragni, Enrico","Mangiavini, Laura","Vigano, Marco","Brini, Anna Teresa","Peretti, Giuseppe Michele","Banfi, Giuseppe","de Girolamo, Laura","32438454"],"abstract":["The pandemic spread of the new COVID-19 coronavirus infection in China first, and all over the world at present, has become a global health emergency due to the rapidly increasing number of affected patients. Currently, a clear relationship between COVID-19 infection incidence and/or complications due to chronic or occasional treatments for other pathologies is still not clear, albeit COVID-19 pandemic may condition the treatment strategy of complex disorders, as osteoarthritis (OA). Importantly, OA is the most common age-related joint disease affecting more than 80% of people older than the age of 55, an age burden also shared with the highest severity in COVID-19 patients. OA patients often show a large array of concomitant pathologies such as diabetes, inflammation and cardiovascular diseases that are again shared with COVID-19 patients and may therefore increase complications. Moreover, different OA treatments such as NSAIDs, paracetamol, corticosteroids, opioids or other molecules have a wide array of iatrogenic effects, potentially increasing COVID-19 secondary infection incidence or complications. In this review we critically analyse the evidences on either negative or positive effect of drugs commonly used to manage OA in this particular scenario. This would provide orthopaedic surgeons at first, and physicians, pharmacologists and clinicians at general, a comprehensive description about the safety of the current pharmacological approaches and a decision making tool to treat their OA patients as the coronavirus pandemic continues."],"journal":"Clin Pharmacol Ther","authors":["Ragni, Enrico","Mangiavini, Laura","Vigano, Marco","Brini, Anna Teresa","Peretti, Giuseppe Michele","Banfi, Giuseppe","de Girolamo, Laura"],"date":"2020-05-22T11:00:00Z","year":2020,"_id":"32438454","source":"PubMed","week":"202021|May 18 - May 24","doi":"10.1002/cpt.1910","keywords":["nsaids","sars-cov-2","corticosteroids","inflammation","mabs","opioids","osteoarthritis","paracetamol"],"locations":["China","pharmacologists"],"countries":["China"],"countries_codes":["CHN|China"],"e_drugs":["Acetaminophen"],"topics":["Treatment","Prevention"],"weight":1,"_version_":1667521393625923584,"score":9.490897,"similar":[{"pmid":32302279,"title":"15 Smartphone Apps for Older Adults to Use While in Isolation During the COVID-19 Pandemic.","text":["15 Smartphone Apps for Older Adults to Use While in Isolation During the COVID-19 Pandemic.","The maintenance of well-being, healthcare, and social connection is crucial for older adults (OA) and has become a topic of debate as much of the world faces lockdown during the coronavirus disease 2019 (COVID-19) pandemic. OAs have been advised to isolate themselves because they are at higher risk for developing serious complications from severe acute respiratory syndrome coronavirus. Additionally, nursing homes and assisted-living facilities across the country have closed their doors to visitors to protect their residents. Mobile technology such as applications (apps) could provide a valuable tool to help families stay connected, and to help OAs maintain mobility and link them to resources that encourage physical and mental well-being. Apps could address cognitive, visual, and hearing impairments. Our objective was to narratively summarize 15 apps that address physical and cognitive limitations and have the potential to improve OAs' quality of life, especially during social distancing or self-quarantine.","West J Emerg Med","Banskota, Swechya","Healy, Margaret","Goldberg, Elizabeth M","32302279"],"abstract":["The maintenance of well-being, healthcare, and social connection is crucial for older adults (OA) and has become a topic of debate as much of the world faces lockdown during the coronavirus disease 2019 (COVID-19) pandemic. OAs have been advised to isolate themselves because they are at higher risk for developing serious complications from severe acute respiratory syndrome coronavirus. Additionally, nursing homes and assisted-living facilities across the country have closed their doors to visitors to protect their residents. Mobile technology such as applications (apps) could provide a valuable tool to help families stay connected, and to help OAs maintain mobility and link them to resources that encourage physical and mental well-being. Apps could address cognitive, visual, and hearing impairments. Our objective was to narratively summarize 15 apps that address physical and cognitive limitations and have the potential to improve OAs' quality of life, especially during social distancing or self-quarantine."],"journal":"West J Emerg Med","authors":["Banskota, Swechya","Healy, Margaret","Goldberg, Elizabeth M"],"date":"2020-04-18T11:00:00Z","year":2020,"_id":"32302279","source":"PubMed","week":"202016|Apr 13 - Apr 19","doi":"10.5811/westjem.2020.4.47372","topics":["Prevention"],"weight":1,"_version_":1666138494871797761,"score":328.95627},{"pmid":32447629,"title":"COVID-19 and NSAIDS: A Narrative Review of Knowns and Unknowns.","text":["COVID-19 and NSAIDS: A Narrative Review of Knowns and Unknowns.","Concern about the appropriate role of nonsteroidal anti-inflammatory drugs (NSAIDs) in COVID-19 speculate that NSAIDs, in particular ibuprofen, may upregulate the entry point for the virus, the angiotensin-converting enzyme (ACE) 2 receptors and increase susceptibility to the virus or worsen symptoms in existing disease. Adverse outcomes with COVID-19 have been linked to cytokine storm but the most effective way to address exaggerated inflammatory response is complex and unclear. The Expert Working Group on the Commission of Human Medicines in the UK and other organizations have stated that there is insufficient evidence to establish a link between ibuprofen and susceptibility to or exacerbation of COVID-19. NSAID use must also be categorized by whether the drugs are relatively low-dose over-the-counter oral products taken occasionally versus higher-dose or parenteral NSAIDs. Even if evidence emerged arguing for or against NSAIDs in this setting, it is unclear if this evidence would apply to all NSAIDs at all doses in all dosing regimens. Paracetamol (acetaminophen) has been proposed as an alternative to NSAIDs but there are issues with liver toxicity at high doses. There are clearly COVID-19 cases where NSAIDs should not be used, but there is no strong evidence that NSAIDs must be avoided in all patients with COVID-19; clinicians must weigh these choices on an individual basis.","Pain Ther","Pergolizzi, Joseph V Jr","Varrassi, Giustino","Magnusson, Peter","LeQuang, Jo Ann","Paladini, Antonella","Taylor, Robert","Wollmuth, Charles","Breve, Frank","Christo, Paul","32447629"],"abstract":["Concern about the appropriate role of nonsteroidal anti-inflammatory drugs (NSAIDs) in COVID-19 speculate that NSAIDs, in particular ibuprofen, may upregulate the entry point for the virus, the angiotensin-converting enzyme (ACE) 2 receptors and increase susceptibility to the virus or worsen symptoms in existing disease. Adverse outcomes with COVID-19 have been linked to cytokine storm but the most effective way to address exaggerated inflammatory response is complex and unclear. The Expert Working Group on the Commission of Human Medicines in the UK and other organizations have stated that there is insufficient evidence to establish a link between ibuprofen and susceptibility to or exacerbation of COVID-19. NSAID use must also be categorized by whether the drugs are relatively low-dose over-the-counter oral products taken occasionally versus higher-dose or parenteral NSAIDs. Even if evidence emerged arguing for or against NSAIDs in this setting, it is unclear if this evidence would apply to all NSAIDs at all doses in all dosing regimens. Paracetamol (acetaminophen) has been proposed as an alternative to NSAIDs but there are issues with liver toxicity at high doses. There are clearly COVID-19 cases where NSAIDs should not be used, but there is no strong evidence that NSAIDs must be avoided in all patients with COVID-19; clinicians must weigh these choices on an individual basis."],"journal":"Pain Ther","authors":["Pergolizzi, Joseph V Jr","Varrassi, Giustino","Magnusson, Peter","LeQuang, Jo Ann","Paladini, Antonella","Taylor, Robert","Wollmuth, Charles","Breve, Frank","Christo, Paul"],"date":"2020-05-25T11:00:00Z","year":2020,"_id":"32447629","source":"PubMed","week":"202022|May 25 - May 31","doi":"10.1007/s40122-020-00173-5","keywords":["acetaminophen","covid-19","ibuprofen","nsaids","paracetamol","sars-ncov-2 virus"],"locations":["GBR"],"countries":["United Kingdom"],"countries_codes":["GBR|United Kingdom"],"topics":["Treatment"],"weight":1,"_version_":1667698385943003136,"score":273.04062},{"pmid":32402114,"title":"Managing ocular allergy in the time of COVID-19.","text":["Managing ocular allergy in the time of COVID-19.","This spring, the majority of allergic patients are confined to their homes due to COVID-19 pandemic restrictions. In the following weeks, these restrictions will be reduced andpeople will be allowed to take walks, go jogging, and return to work.Spring is the time for ocular allergy (OA) to emerge with signs and symptoms consequent to increasing pollen counts. Even when wearing a mask, the eyes may remain unprotectedleading to an increase in ocular symptoms and patients seeking treatment forOA. However, access to routine consultation may remain problematic for many patients.","Allergy","Leonardi, A","Fauquert, J L","Doan, S","Delgado, L","Andant, N","Klimek, L","Bozkurt, B","32402114"],"abstract":["This spring, the majority of allergic patients are confined to their homes due to COVID-19 pandemic restrictions. In the following weeks, these restrictions will be reduced andpeople will be allowed to take walks, go jogging, and return to work.Spring is the time for ocular allergy (OA) to emerge with signs and symptoms consequent to increasing pollen counts. Even when wearing a mask, the eyes may remain unprotectedleading to an increase in ocular symptoms and patients seeking treatment forOA. However, access to routine consultation may remain problematic for many patients."],"journal":"Allergy","authors":["Leonardi, A","Fauquert, J L","Doan, S","Delgado, L","Andant, N","Klimek, L","Bozkurt, B"],"date":"2020-05-14T11:00:00Z","year":2020,"_id":"32402114","source":"PubMed","week":"202020|May 11 - May 17","doi":"10.1111/all.14361","topics":["Prevention"],"weight":1,"_version_":1666714494966956032,"score":259.1571},{"pmid":32259288,"title":"Caring for patients with pain during the COVID-19 pandemic: consensus recommendations from an international expert panel.","text":["Caring for patients with pain during the COVID-19 pandemic: consensus recommendations from an international expert panel.","Chronic pain causes significant suffering, limitation of daily activities and reduced quality of life. Infection from COVID-19 is responsible for an ongoing pandemic that causes severe acute respiratory syndrome, leading to systemic complications and death. Led by the World Health Organization, healthcare systems across the world are engaged in limiting the spread of infection. As a result, all elective surgical procedures, outpatient procedures and patient visits, including pain management services, have been postponed or cancelled. This has affected the care of chronic pain patients. Most are elderly with multiple comorbidities, which puts them at risk of COVID-19 infection. Important considerations that need to be recognised during this pandemic for chronic pain patients include: ensuring continuity of care and pain medications, especially opioids; use of telemedicine; maintaining biopsychosocial management; use of anti-inflammatory drugs; use of steroids; and prioritising necessary procedural visits. There are no guidelines to inform physicians and healthcare providers engaged in caring for patients with pain during this period of crisis. We assembled an expert panel of pain physicians, psychologists and researchers from North America and Europe to formulate recommendations to guide practice. As the COVID-19 situation continues to evolve rapidly, these recommendations are based on the best available evidence and expert opinion at this present time and may need adapting to local workplace policies.","Anaesthesia","Shanthanna, H","Strand, N H","Provenzano, D A","Lobo, C A","Eldabe, S","Bhatia, A","Wegener, J","Curtis, K","Cohen, S P","Narouze, S","32259288"],"abstract":["Chronic pain causes significant suffering, limitation of daily activities and reduced quality of life. Infection from COVID-19 is responsible for an ongoing pandemic that causes severe acute respiratory syndrome, leading to systemic complications and death. Led by the World Health Organization, healthcare systems across the world are engaged in limiting the spread of infection. As a result, all elective surgical procedures, outpatient procedures and patient visits, including pain management services, have been postponed or cancelled. This has affected the care of chronic pain patients. Most are elderly with multiple comorbidities, which puts them at risk of COVID-19 infection. Important considerations that need to be recognised during this pandemic for chronic pain patients include: ensuring continuity of care and pain medications, especially opioids; use of telemedicine; maintaining biopsychosocial management; use of anti-inflammatory drugs; use of steroids; and prioritising necessary procedural visits. There are no guidelines to inform physicians and healthcare providers engaged in caring for patients with pain during this period of crisis. We assembled an expert panel of pain physicians, psychologists and researchers from North America and Europe to formulate recommendations to guide practice. As the COVID-19 situation continues to evolve rapidly, these recommendations are based on the best available evidence and expert opinion at this present time and may need adapting to local workplace policies."],"journal":"Anaesthesia","authors":["Shanthanna, H","Strand, N H","Provenzano, D A","Lobo, C A","Eldabe, S","Bhatia, A","Wegener, J","Curtis, K","Cohen, S P","Narouze, S"],"date":"2020-04-08T11:00:00Z","year":2020,"_id":"32259288","source":"PubMed","week":"202015|Apr 06 - Apr 12","doi":"10.1111/anae.15076","keywords":["covid-19","chronic pain","opioids","recommendations","steroids"],"e_drugs":["Steroids"],"topics":["Prevention"],"weight":1,"_version_":1666138493172056066,"score":176.29498},{"pmid":32205186,"pmcid":"PMC7102591","title":"COVID-19 infection and rheumatoid arthritis: Faraway, so close!","text":["COVID-19 infection and rheumatoid arthritis: Faraway, so close!","The outbreak of the new coronavirus infections COVID-19 in December 2019 in China has quickly become a global health emergency. Given the lack of specific anti-viral therapies, the current management of severe acute respiratory syndrome coronaviruses (SARS-CoV-2) is mainly supportive, even though several compounds are now under investigation for the treatment of this life-threatening disease. COVID-19 pandemic is certainly conditioning the treatment strategy of a complex disorder as rheumatoid arthritis (RA), whose infectious risk is increased compared to the general population because of an overall impairment of immune system typical of autoimmune diseases combined with the iatrogenic effect generated by corticosteroids and immunosuppressive drugs. However, the increasing knowledge about the pathophysiology of SARS-CoV-2 infection is leading to consider some anti-rheumatic drugs as potential treatment options for the management of COVID-19. In this review we will critically analyse the evidences on either positive or negative effect of drugs commonly used to treat RA in this particular scenario, in order to optimize the current approach to RA patients.","Autoimmun Rev","Favalli, Ennio Giulio","Ingegnoli, Francesca","De Lucia, Orazio","Cincinelli, Gilberto","Cimaz, Rolando","Caporali, Roberto","32205186"],"abstract":["The outbreak of the new coronavirus infections COVID-19 in December 2019 in China has quickly become a global health emergency. Given the lack of specific anti-viral therapies, the current management of severe acute respiratory syndrome coronaviruses (SARS-CoV-2) is mainly supportive, even though several compounds are now under investigation for the treatment of this life-threatening disease. COVID-19 pandemic is certainly conditioning the treatment strategy of a complex disorder as rheumatoid arthritis (RA), whose infectious risk is increased compared to the general population because of an overall impairment of immune system typical of autoimmune diseases combined with the iatrogenic effect generated by corticosteroids and immunosuppressive drugs. However, the increasing knowledge about the pathophysiology of SARS-CoV-2 infection is leading to consider some anti-rheumatic drugs as potential treatment options for the management of COVID-19. In this review we will critically analyse the evidences on either positive or negative effect of drugs commonly used to treat RA in this particular scenario, in order to optimize the current approach to RA patients."],"journal":"Autoimmun Rev","authors":["Favalli, Ennio Giulio","Ingegnoli, Francesca","De Lucia, Orazio","Cincinelli, Gilberto","Cimaz, Rolando","Caporali, Roberto"],"date":"2020-03-25T11:00:00Z","year":2020,"_id":"32205186","source":"PubMed","week":"202013|Mar 23 - Mar 29","doi":"10.1016/j.autrev.2020.102523","keywords":["covid-19","coronavirus","cytokine release syndrome","dmards","rheumatoid arthritis","treatment"],"locations":["China"],"countries":["China"],"countries_codes":["CHN|China"],"topics":["Treatment"],"weight":1,"_version_":1666138490140622848,"score":173.20795}]}